BR112020003276A2 - métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano - Google Patents

métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano Download PDF

Info

Publication number
BR112020003276A2
BR112020003276A2 BR112020003276-0A BR112020003276A BR112020003276A2 BR 112020003276 A2 BR112020003276 A2 BR 112020003276A2 BR 112020003276 A BR112020003276 A BR 112020003276A BR 112020003276 A2 BR112020003276 A2 BR 112020003276A2
Authority
BR
Brazil
Prior art keywords
oil
compositions
fact
composition
patient
Prior art date
Application number
BR112020003276-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Scott Whitcup
Orest Olejnik
Mike Garst
Peter A. Simmons
Original Assignee
Akrivista, LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akrivista, LLC filed Critical Akrivista, LLC
Publication of BR112020003276A2 publication Critical patent/BR112020003276A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235—Foeniculum (fennel)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
BR112020003276-0A 2017-08-18 2018-08-17 métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano BR112020003276A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547553P 2017-08-18 2017-08-18
US62/547,553 2017-08-18
PCT/US2018/046918 WO2019036625A1 (en) 2017-08-18 2018-08-17 METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE

Publications (1)

Publication Number Publication Date
BR112020003276A2 true BR112020003276A2 (pt) 2020-09-01

Family

ID=65363005

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020003276-0A BR112020003276A2 (pt) 2017-08-18 2018-08-17 métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano

Country Status (7)

Country Link
US (2) US11622982B2 (enExample)
EP (1) EP3668474A4 (enExample)
JP (1) JP7311160B2 (enExample)
CN (2) CN114376961A (enExample)
BR (1) BR112020003276A2 (enExample)
CA (1) CA3072494A1 (enExample)
WO (1) WO2019036625A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3500344A4 (en) 2016-08-19 2020-08-05 Akrivista, LLC METHODS OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
CA3072494A1 (en) 2017-08-18 2019-02-21 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
JP7526718B2 (ja) * 2019-02-27 2024-08-01 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
PL3888634T3 (pl) * 2020-03-31 2023-09-11 Oy Finnsusp Ab Preparat oftalmiczny i jego zastosowanie
EP3919047A1 (en) * 2020-06-03 2021-12-08 AZAD Pharma AG Microemulsion for the treatment of dry eye syndrome
ES2916152A1 (es) * 2020-12-28 2022-06-28 Univ Valladolid Compuestos para su uso en la prevencion y/o tratamiento de la inflamacion y el estres oxidativo del segmento anterior del ojo
CN112842936A (zh) * 2021-03-15 2021-05-28 傅博 一种眼部清洁液及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4146499A (en) 1976-09-18 1979-03-27 Rosano Henri L Method for preparing microemulsions
US4585656A (en) 1984-08-20 1986-04-29 Rosenthal Harold R Treatment of herpes
CA2052950A1 (en) 1990-10-10 1992-04-11 David P. Evitts Aqueous ophthalmic microemulsions of tepoxalin
HK1004520A1 (en) 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
US5527488A (en) * 1992-08-07 1996-06-18 Amway Corporation High viscosity anhydrous makeup remover gel
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US20030086986A1 (en) 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US7262224B2 (en) * 1999-11-30 2007-08-28 Hanna Isul Skin Therapy, Inc. Cosmetic rejuvenating and healing product, method of its manufacture and uses thereof
PL369960A1 (en) 2001-10-11 2005-05-02 Alcon, Inc. Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
US6559182B1 (en) 2001-11-07 2003-05-06 Purcell Jojoba International, Llc Method for treatment of enveloped viruses using jojoba oil esters
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
WO2006004577A2 (en) 2004-03-12 2006-01-12 Melbj Holdings, Llc Lubricant for the ocular surface
JP5272307B2 (ja) 2004-07-16 2013-08-28 大正製薬株式会社 水性点眼剤
US20060148686A1 (en) 2004-12-30 2006-07-06 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
US9161905B2 (en) 2005-01-12 2015-10-20 Ocular Research Of Boston, Inc. Dry eye treatment
JP2006233398A (ja) 2005-02-23 2006-09-07 Daiwa Kagaku Kogyo Kk アボガド油及びアボガド油不けん化物を処理したことを特徴とする機能化繊維材料および機能化繊維材料の処理方法。
CN101175488B (zh) 2005-05-17 2012-04-18 萨可德公司 治疗眼病的组合物和方法
CA2679448A1 (en) 2007-02-28 2008-09-04 Aciex, Inc. Methods and compositions for normalizing meibomian gland secretions
FR2916636B1 (fr) * 2007-05-29 2009-09-04 Octalia Technologies Vehicule sous forme d'une emulsion huile-dans-eau notamment destine a une utilisation ophtalmique ou dermocosmetique
US8669241B2 (en) 2008-12-02 2014-03-11 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
MX2011013060A (es) 2009-06-05 2012-02-28 Aciex Therapeutics Inc Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
DK2437762T3 (da) 2009-06-05 2017-11-20 Allergan Inc Kunstige tårer og terapeutiske anvendelser
KR101690817B1 (ko) 2009-06-30 2016-12-28 라이온 가부시키가이샤 안과용 조성물
US8909327B1 (en) 2010-06-23 2014-12-09 Allergan, Inc. Instrument and method for diagnosing dry eye in a patient
JP5952302B2 (ja) 2010-12-29 2016-07-13 ニチャミン、ルイス・ディー 眼の治療のための方法及びキット
JP6093701B2 (ja) 2011-07-08 2017-03-08 ロート製薬株式会社 眼科用水性組成物
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
PT2787969T (pt) 2011-12-07 2021-11-09 Allergan Inc Entrega eficiente de lípidos para o filme lacrimal humano utilizando um sistema de emulsão sensível ao sal
ITFI20120044A1 (it) 2012-03-01 2013-09-02 Biodue Spa Formulazione ad uso oftalmico comprendente olio di jojoba.
JP5988855B2 (ja) 2012-06-27 2016-09-07 ロート製薬株式会社 水性眼科組成物
EP3117838B1 (en) 2014-03-10 2020-09-16 Saraya Co., Ltd. Composition containing sophorolipid, physiologically active substance and oil and fat, and method of producing said composition
CA2967413C (en) 2014-11-25 2023-08-15 Allergan, Inc. Ophthalmic compositions containing omega-3 oils stabilized by antioxidants
DK3266446T3 (en) 2016-07-07 2019-02-11 Salvat Lab Sa Eye preparation comprising castor oil and medium chain triglyceride
EP3500344A4 (en) * 2016-08-19 2020-08-05 Akrivista, LLC METHODS OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
CN106389218A (zh) 2016-10-28 2017-02-15 林振慧 一种眼部凝露
CA3072494A1 (en) 2017-08-18 2019-02-21 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye

Also Published As

Publication number Publication date
CN114376961A (zh) 2022-04-22
EP3668474A4 (en) 2021-05-26
US20200164013A1 (en) 2020-05-28
JP2020531462A (ja) 2020-11-05
US12220439B2 (en) 2025-02-11
US11622982B2 (en) 2023-04-11
JP7311160B2 (ja) 2023-07-19
US20230233637A1 (en) 2023-07-27
EP3668474A1 (en) 2020-06-24
CN111295169A (zh) 2020-06-16
WO2019036625A1 (en) 2019-02-21
CA3072494A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
US12220439B2 (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
JP2022177281A (ja) ドライアイ症候群を診断及び治療する方法ならびにヒト眼を治療するための組成物
US20240374678A1 (en) Ophthalmic composition for treatment of dry eye disease
Yeu et al. Lotilaner ophthalmic solution, 0.25%, for the treatment of demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1)
Tauber et al. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
Holzchuh et al. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin
Al-Saedi et al. Dry eye disease: present challenges in the management and future trends
CN111182893A (zh) 包含f6h8的眼用组合物
KR20210080388A (ko) 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물
Yeu et al. Treatment of Demodex blepharitis: a prospective, randomized, controlled, double-masked clinical trial comparing topical lotilaner ophthalmic solution, 0.25% eyedrops to vehicle
Schmidl et al. A phase II, multicenter, randomized, placebo-controlled, double-masked trial of a topical estradiol ophthalmic formulation in postmenopausal women with moderate-to-severe dry eye disease
CN110013498A (zh) 一种含盐酸奥洛他定的滴眼液及其制备方法
CN109789182A (zh) 治疗干眼综合征的方法
US20170239307A1 (en) Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies
HK40073074A (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
RU2828769C2 (ru) Офтальмологические композиции для лечения синдрома сухого глаза
HK40007121A (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
HK40028751A (en) Ophthalmic compositions comprising f6h8
Tantra et al. A CLINICAL STUDY ON EFFICACY OF JEEVANTYAADI GHRITA IN SUSHKAKSHIPAAKA (DRY EYE)
Yang Dry Eye Treatment–For Red Irritated Dry Eyes
Yang Best Cure for Dry Eyes Now?

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements